CA2683862C - Fusion protein of collagen-binding domain and parathyroid hormone - Google Patents
Fusion protein of collagen-binding domain and parathyroid hormone Download PDFInfo
- Publication number
- CA2683862C CA2683862C CA2683862A CA2683862A CA2683862C CA 2683862 C CA2683862 C CA 2683862C CA 2683862 A CA2683862 A CA 2683862A CA 2683862 A CA2683862 A CA 2683862A CA 2683862 C CA2683862 C CA 2683862C
- Authority
- CA
- Canada
- Prior art keywords
- pth
- collagen
- seq
- bone
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 217
- 102000003982 Parathyroid hormone Human genes 0.000 title claims abstract description 207
- 239000000199 parathyroid hormone Substances 0.000 title claims abstract description 207
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 142
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 142
- 229920001436 collagen Polymers 0.000 title claims abstract description 120
- 102000008186 Collagen Human genes 0.000 title claims abstract description 119
- 108010035532 Collagen Proteins 0.000 title claims abstract description 119
- 230000027455 binding Effects 0.000 title claims abstract description 91
- 229960001319 parathyroid hormone Drugs 0.000 title abstract description 158
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 160
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 154
- 229920001184 polypeptide Polymers 0.000 claims abstract description 153
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 claims abstract description 89
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 claims abstract description 89
- 239000000018 receptor agonist Substances 0.000 claims abstract description 55
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 55
- 210000000130 stem cell Anatomy 0.000 claims abstract description 38
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 18
- 230000003779 hair growth Effects 0.000 claims abstract description 17
- 230000008468 bone growth Effects 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims description 60
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 53
- 239000007943 implant Substances 0.000 claims description 34
- 230000003442 weekly effect Effects 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- 230000000399 orthopedic effect Effects 0.000 claims description 9
- 230000008467 tissue growth Effects 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 241000193403 Clostridium Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000011327 Increased bone mineral density Diseases 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 105
- 229940044551 receptor antagonist Drugs 0.000 abstract description 37
- 239000002464 receptor antagonist Substances 0.000 abstract description 37
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 abstract description 25
- 102000043299 Parathyroid hormone-related Human genes 0.000 abstract description 25
- 239000005557 antagonist Substances 0.000 abstract description 24
- 239000000556 agonist Substances 0.000 abstract description 18
- 206010027476 Metastases Diseases 0.000 abstract description 14
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 abstract description 12
- 201000006409 renal osteodystrophy Diseases 0.000 abstract description 12
- 230000009401 metastasis Effects 0.000 abstract description 11
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 11
- 239000012634 fragment Substances 0.000 abstract description 10
- 125000001151 peptidyl group Chemical group 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 61
- 229910052500 inorganic mineral Inorganic materials 0.000 description 53
- 239000011707 mineral Substances 0.000 description 53
- 235000010755 mineral Nutrition 0.000 description 53
- 241001465754 Metazoa Species 0.000 description 41
- 108700015210 PTH-CBD fusion Proteins 0.000 description 34
- 238000000034 method Methods 0.000 description 28
- 239000007924 injection Substances 0.000 description 27
- 238000002347 injection Methods 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- 230000001737 promoting effect Effects 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 108060005980 Collagenase Proteins 0.000 description 11
- 102000029816 Collagenase Human genes 0.000 description 11
- 239000012867 bioactive agent Substances 0.000 description 11
- 229960002424 collagenase Drugs 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 230000001054 cortical effect Effects 0.000 description 10
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- -1 polyethylene Polymers 0.000 description 8
- 208000001132 Osteoporosis Diseases 0.000 description 7
- 239000012148 binding buffer Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 6
- 230000001195 anabolic effect Effects 0.000 description 6
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 108010074860 Factor Xa Proteins 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003416 augmentation Effects 0.000 description 4
- LNQHREYHFRFJAU-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) pentanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(=O)ON1C(=O)CCC1=O LNQHREYHFRFJAU-UHFFFAOYSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 108010049264 Teriparatide Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000004053 dental implant Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 229960005460 teriparatide Drugs 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 2
- 206010061728 Bone lesion Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000193159 Hathewaya histolytica Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000013230 female C57BL/6J mice Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YKGRXSLQYRREKO-DFOPOJAZSA-N 101380-54-5 Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 YKGRXSLQYRREKO-DFOPOJAZSA-N 0.000 description 1
- RVJFYAXPARXKHK-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)-4-hydrazinylpyridine-3-carboxylic acid propan-2-ylidenehydrazine Chemical compound CC(C)=NN.NNc1ccnc(N2C(=O)CCC2=O)c1C(O)=O RVJFYAXPARXKHK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019030 Hair colour changes Diseases 0.000 description 1
- 101000920185 Hathewaya histolytica Collagenase ColG Proteins 0.000 description 1
- 101000920186 Hathewaya histolytica Collagenase ColH Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 1
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100537302 Mus musculus Itfg1 gene Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 206010033964 Parathyroid tumour benign Diseases 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000011444 antiresorptive therapy Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 101150046500 colH gene Proteins 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000051132 human PTH1R Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 201000003686 parathyroid adenoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 208000014643 parathyroid gland adenoma Diseases 0.000 description 1
- 108010084846 parathyroid hormone (7-34) Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- JIQXKYSNGXUDJU-UHFFFAOYSA-N propan-2-ylidenehydrazine Chemical compound CC(C)=NN JIQXKYSNGXUDJU-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 208000028198 tertiary hyperparathyroidism Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010074209 tuberoinfundibular peptide 39 Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Hematology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2930681A CA2930681C (en) | 2007-04-09 | 2008-04-09 | Fusion protein of collagen-binding domain and parathyroid hormone |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92243307P | 2007-04-09 | 2007-04-09 | |
| US60/922,433 | 2007-04-09 | ||
| PCT/US2008/004589 WO2008124166A2 (en) | 2007-04-09 | 2008-04-09 | Fusion proteins of collagen-binding domain and parathyroid hormone |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2930681A Division CA2930681C (en) | 2007-04-09 | 2008-04-09 | Fusion protein of collagen-binding domain and parathyroid hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2683862A1 CA2683862A1 (en) | 2008-10-16 |
| CA2683862C true CA2683862C (en) | 2016-08-02 |
Family
ID=39831527
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2683862A Active CA2683862C (en) | 2007-04-09 | 2008-04-09 | Fusion protein of collagen-binding domain and parathyroid hormone |
| CA2930681A Active CA2930681C (en) | 2007-04-09 | 2008-04-09 | Fusion protein of collagen-binding domain and parathyroid hormone |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2930681A Active CA2930681C (en) | 2007-04-09 | 2008-04-09 | Fusion protein of collagen-binding domain and parathyroid hormone |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US8450273B2 (OSRAM) |
| EP (2) | EP2155874B1 (OSRAM) |
| JP (4) | JP5520811B2 (OSRAM) |
| CA (2) | CA2683862C (OSRAM) |
| DK (2) | DK2155874T3 (OSRAM) |
| ES (2) | ES2583002T3 (OSRAM) |
| WO (1) | WO2008124166A2 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213517A (zh) * | 2017-05-17 | 2017-09-29 | 宁波大学 | 一种复合骨水泥及其制备方法 |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2155874T3 (en) * | 2007-04-09 | 2016-08-01 | Univ Arkansas | FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone |
| US20110294192A1 (en) * | 2008-11-19 | 2011-12-01 | Tohoku University | Fusion collagenase in which affinity tag is linked and method for producing the same |
| EP2405008A1 (en) * | 2010-07-06 | 2012-01-11 | LanthioPep B.V. | Bacterial surface display of thioether-bridge-containing peptides |
| US9173919B2 (en) | 2011-02-16 | 2015-11-03 | Purdue Research Foundation | Collagen-targeted nanoparticles |
| JP5512887B2 (ja) * | 2011-05-13 | 2014-06-04 | 学校法人北里研究所 | 成長因子アンカーリング型骨移植材料および成長因子アンカーリング型骨移植材料製造用キット |
| ES2816009T3 (es) * | 2011-12-14 | 2021-03-31 | Univ Arkansas | Administración de agentes terapéuticos mediante una proteína de unión a colágeno |
| US9526765B2 (en) | 2012-02-09 | 2016-12-27 | The Kitasato Institute | Delivery of therapeutic agents by a collagen binding protein |
| US8969290B2 (en) | 2012-06-26 | 2015-03-03 | Worcester Polytechnic Institute | Matrix scaffold with antimicrobial activity |
| WO2016085280A1 (ko) | 2014-11-28 | 2016-06-02 | 서울대학교산학협력단 | 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도 |
| US11213613B2 (en) | 2015-06-12 | 2022-01-04 | Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences | Three-dimensional tissue scaffold with stem cell attracting element and use thereof |
| BR112018017091A2 (pt) | 2016-03-01 | 2019-01-02 | Ascendis Pharma Bone Diseases As | profármacos de pth |
| CN109789189B (zh) | 2016-09-29 | 2024-01-23 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth化合物的剂量方案 |
| NZ751745A (en) | 2016-09-29 | 2023-05-26 | Ascendis Pharma Bone Diseases As | Pth compounds with low peak-to-trough ratios |
| ES3012647T3 (en) | 2016-09-29 | 2025-04-09 | Ascendis Pharma Bone Diseases As | Controlled-release pth compounds |
| CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| WO2018148573A1 (en) * | 2017-02-10 | 2018-08-16 | The Board Of Trustees Of The University Of Arkansas | Collagen-binding agent compositions and methods of using the same |
| GB201706781D0 (en) | 2017-04-28 | 2017-06-14 | Univ Sheffield | Parathyroid hormone fusion polypeptide |
| JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| KR101964376B1 (ko) * | 2017-09-29 | 2019-04-01 | 주식회사 나이벡 | 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료 |
| EP3796941A4 (en) | 2018-05-30 | 2022-12-28 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| KR102891411B1 (ko) | 2019-02-11 | 2025-11-25 | 아센디스 파마 본 디지즈 에이/에스 | Pth 접합체의 액체 약학 제제 |
| WO2021030196A1 (en) * | 2019-08-09 | 2021-02-18 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins comprising parathyroid hormone for controlled and sustained release |
| US12403179B2 (en) | 2021-02-18 | 2025-09-02 | The Board Of Trustees Of The University Of Arkansas | Release of growth factors at wound healing stages |
| JP2025534350A (ja) | 2022-09-30 | 2025-10-15 | エクステンド バイオサイエンシズ インコーポレーテッド | 長時間作用型副甲状腺ホルモン |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516421D0 (en) | 1985-06-28 | 1985-07-31 | Biotechnology Interface Ltd | Fibronectins |
| WO1994022468A1 (en) | 1993-04-02 | 1994-10-13 | Anticancer, Inc. | Method for delivering beneficial compositions to hair follicles |
| US5925552A (en) | 1996-04-25 | 1999-07-20 | Medtronic, Inc. | Method for attachment of biomolecules to medical devices surfaces |
| WO1998004591A1 (en) | 1996-07-31 | 1998-02-05 | The General Hospital Corporation | Novel parathyroid hormone-related peptide analogs |
| US6428579B1 (en) | 1998-07-01 | 2002-08-06 | Brown University Research Foundation | Implantable prosthetic devices coated with bioactive molecules |
| US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| US7601685B2 (en) * | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| EP1151116A1 (en) | 1999-02-19 | 2001-11-07 | Terumo Kabushiki Kaisha | Collagen-binding physiologically active polypeptide |
| JP2001190280A (ja) * | 1999-02-19 | 2001-07-17 | Terumo Corp | コラーゲン結合性生理活性ポリペプチド |
| US20020102709A1 (en) * | 1999-02-19 | 2002-08-01 | Tetsuya Ishikawa | Collagen-binding physiologically active polypeptide |
| US6908994B1 (en) * | 1999-05-10 | 2005-06-21 | The Texas A&M University System | Collagen-binding proteins from enterococcal bacteria |
| US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| US20040053368A1 (en) * | 2000-08-15 | 2004-03-18 | Tetsuya Ishikawa | Collagen-binding hybrid polypeptide |
| JP2002058485A (ja) | 2000-08-16 | 2002-02-26 | Terumo Corp | コラーゲン結合性を有する骨形成促進融合蛋白質 |
| US20020063621A1 (en) | 2000-09-01 | 2002-05-30 | Next Planet, Inc. | Method and apparatus for device communications |
| US6812217B2 (en) | 2000-12-04 | 2004-11-02 | Medtronic, Inc. | Medical device and methods of use |
| JP4560291B2 (ja) | 2001-12-18 | 2010-10-13 | イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ | 組織操作のための成長因子改変タンパク質マトリクス |
| JP4750416B2 (ja) * | 2002-07-25 | 2011-08-17 | ザ ジェネラル ホスピタル コーポレイション | 副甲状腺ホルモン受容体の活性化と造血前駆細胞の増殖 |
| US7060299B2 (en) | 2002-12-31 | 2006-06-13 | Battelle Memorial Institute | Biodegradable microparticles that stabilize and control the release of proteins |
| ES2269973T3 (es) | 2003-02-13 | 2007-04-01 | Synthes Ag Chur | Mezcla inyectable para sustituir un tejido oseo. |
| US20040220094A1 (en) | 2003-05-01 | 2004-11-04 | Skinner Keith K. | Inverse agonist and agonist peptides that stimulate/inhibit hair growth |
| EP1680073B1 (en) | 2003-10-21 | 2013-01-02 | IGF Oncology, LLC | Compounds and method for treating cancer |
| WO2005046798A1 (en) * | 2003-11-12 | 2005-05-26 | Nps Allelix Corp. | Treatment of bone loss utilizing full length parathyroid hormone |
| EP1557176A1 (en) | 2004-01-26 | 2005-07-27 | Ferring B.V. | Treatment of bone metastases by means of PTH receptor agonists |
| US20090005298A1 (en) | 2004-02-27 | 2009-01-01 | The University Of Western Ontario | Bone Sialoprotein Collagen-Binding Peptides |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| EP1812082B1 (en) | 2004-10-21 | 2013-08-14 | IGF Oncology, LLC | Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| ATE514712T1 (de) | 2005-12-26 | 2011-07-15 | Yantai Zhenghai Bio Technology Co Ltd | Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren |
| DK2155874T3 (en) * | 2007-04-09 | 2016-08-01 | Univ Arkansas | FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone |
| JP2010172247A (ja) | 2009-01-29 | 2010-08-12 | Kitasato Institute | 積層型高密度培養人工組織の製造方法及び積層型高密度培養人工組織 |
| JPWO2011142425A1 (ja) | 2010-05-12 | 2013-07-22 | 国立大学法人 香川大学 | 上皮層含有組織の再生材および再生評価方法 |
| JP5512887B2 (ja) | 2011-05-13 | 2014-06-04 | 学校法人北里研究所 | 成長因子アンカーリング型骨移植材料および成長因子アンカーリング型骨移植材料製造用キット |
| ES2816009T3 (es) | 2011-12-14 | 2021-03-31 | Univ Arkansas | Administración de agentes terapéuticos mediante una proteína de unión a colágeno |
| US9526765B2 (en) | 2012-02-09 | 2016-12-27 | The Kitasato Institute | Delivery of therapeutic agents by a collagen binding protein |
-
2008
- 2008-04-09 DK DK08742686.2T patent/DK2155874T3/en active
- 2008-04-09 US US12/594,547 patent/US8450273B2/en active Active
- 2008-04-09 CA CA2683862A patent/CA2683862C/en active Active
- 2008-04-09 WO PCT/US2008/004589 patent/WO2008124166A2/en not_active Ceased
- 2008-04-09 JP JP2010503048A patent/JP5520811B2/ja active Active
- 2008-04-09 EP EP08742686.2A patent/EP2155874B1/en active Active
- 2008-04-09 ES ES08742686.2T patent/ES2583002T3/es active Active
- 2008-04-09 ES ES16169069.8T patent/ES2675174T3/es active Active
- 2008-04-09 CA CA2930681A patent/CA2930681C/en active Active
- 2008-04-09 EP EP16169069.8A patent/EP3091075B1/en active Active
- 2008-04-09 DK DK16169069.8T patent/DK3091075T3/en active
-
2013
- 2013-05-20 US US13/898,058 patent/US9062300B2/en active Active
- 2013-09-19 JP JP2013194484A patent/JP5821066B2/ja active Active
-
2015
- 2015-06-18 US US14/743,629 patent/US9528099B2/en active Active
- 2015-09-03 JP JP2015173678A patent/JP5989876B2/ja active Active
-
2016
- 2016-08-10 JP JP2016157345A patent/JP6366653B2/ja active Active
- 2016-12-22 US US15/387,817 patent/US10202434B2/en active Active
-
2019
- 2019-01-16 US US16/249,540 patent/US10358471B2/en active Active
- 2019-07-22 US US16/517,988 patent/US10519213B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213517A (zh) * | 2017-05-17 | 2017-09-29 | 宁波大学 | 一种复合骨水泥及其制备方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10519213B2 (en) | Fusion proteins of collagen-binding domain and parathyroid hormone | |
| JP6916918B2 (ja) | 骨形成を促進するための組成物および方法 | |
| KR20200066343A (ko) | 삼중특이적 단백질 및 사용 방법 | |
| JP2010539123A (ja) | 変性疾患の処置のための神経内分泌因子 | |
| US20240092867A1 (en) | Methods and compositions for the treatment of wounds | |
| US9248164B2 (en) | Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material, and method for forming bone | |
| JP2004536056A (ja) | Ｒａｎｋアンタゴニストの療法使用 | |
| JP2021535083A (ja) | Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン | |
| US11529391B2 (en) | Reversing deficient hedgehog signaling restores deficient skeletal regeneration | |
| KR20220097952A (ko) | 암 치료를 위한 her2/4-1bb 이중특이적 융합 단백질 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130211 |